Drug Profile


Alternative Names: Exodif; GT160-246; GT267-004; Tolevamer sodium; Tolevamer toxin binder; Tolevamer-potassium-sodium; Toxin binder - Sanofi Genzyme

Latest Information Update: 14 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genzyme Corporation
  • Class Antidiarrhoeals; Polymers; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Clostridium infections

Most Recent Events

  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 15 Jul 2008 Discontinued - Phase-III for Clostridium infections in Australia (PO)
  • 15 Jul 2008 Discontinued - Phase-III for Clostridium infections in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top